Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EBITDA: 2020-2024

Historic EBITDA for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$130.2 million.

  • Tango Therapeutics' EBITDA rose 142.80% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 15.57%. This contributed to the annual value of -$130.2 million for FY2024, which is 33.01% down from last year.
  • Latest data reveals that Tango Therapeutics reported EBITDA of -$130.2 million as of FY2024, which was down 33.01% from -$97.9 million recorded in FY2023.
  • Over the past 5 years, Tango Therapeutics' EBITDA peaked at -$52.0 million during FY2020, and registered a low of -$130.2 million during FY2024.
  • Moreover, its 3-year median value for EBITDA was -$111.1 million (2022), whereas its average is -$113.0 million.
  • Per our database at Business Quant, Tango Therapeutics' EBITDA slumped by 88.28% in 2022 and then increased by 11.94% in 2023.
  • Tango Therapeutics' EBITDA (Yearly) stood at -$52.0 million in 2020, then dropped by 13.57% to -$59.0 million in 2021, then tumbled by 88.28% to -$111.1 million in 2022, then rose by 11.94% to -$97.9 million in 2023, then plummeted by 33.01% to -$130.2 million in 2024.